6. Since both HCC and BDC express epidermal growth factor receptors (EGFR), we hypothesized that EGFR is a driver of these diseases, and investigated a combination of chemotherapy with EGFR blockade in the form of the TKI erlotinib, based on previously reported erlotinib studies by Philip et al. 10, 11. Here, EGFR is linked to hepatocellular carcinoma.